Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Across the street from MD Anderson, at Texas Children's Hospital, Fivecoat's then-nearly 1-year-old granddaughter Whitney was ...

Blood cancer cases are rising alarmingly among young Indians, with leukemia incidences increasing and bone marrow transplants ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or ...

The work is published in the journal Nano Today. Acute myeloid leukemia is a life-threatening blood cancer with a mortality rate of 90% without prompt intervention. Current chemotherapy treatments ...

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.